Edition:
India

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
2:26am IST
Change (% chg)

$-0.03 (-2.38%)
Prev Close
$1.26
Open
$1.28
Day's High
$1.42
Day's Low
$1.20
Volume
294,311
Avg. Vol
210,030
52-wk High
$3.71
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Vistagen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​.  Full Article

Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Intracoastal Capital Llc::REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>>: AS OF DEC 13 - SEC FILING.  Full Article

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

VistaGen Therapeutics reports Q3 loss per share $0.34
Tuesday, 14 Feb 2017 

VistaGen Therapeutics Inc : VistaGen Therapeutics reports fiscal third quarter 2017 financial results and provides corporate update .Q3 loss per share $0.34.  Full Article

Vistagen Therapeutics provides business outlook
Thursday, 22 Sep 2016 

Vistagen Therapeutics Inc : Vistagen Therapeutics provides business outlook and sets corporate milestones . Says Vistagen expects to report topline data from its NIMH-sponsored Phase 2a study in Q2 of 2017 . Expects to receive FDA fast track designation for AV-101 as adjunctive treatment for MDD during first half of 2017. .Company anticipates topline results for AV-101 from Phase 2b study to be reported in Q3 of 2018.  Full Article

Sphera Funds Management reports 7.6 pct passive stake in Vistagen Therapeutics as of May 11, 2016
Wednesday, 22 Jun 2016 

Vistagen Therapeutics Inc : Sphera Funds Management Ltd reports 7.6 percent passive stake in Vistagen Therapeutics Inc as of May 11, 2016 - Sec filing Source - http://1.usa.gov/28PKYsC (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Vistagen Therapeutics appoints Mark Smith as chief medical officer
Monday, 20 Jun 2016 

Vistagen Therapeutics Inc : Appoints Mark A. Smith, as chief medical officer . Expects to report topline data from phase 2A clinical study in Q2 of 2017 and is preparing to advance AV-101 into a phase 2B .Vistagen Therapeutics appoints pharmaceutical CNS drug development executive Mark A. Smith M.D., PH.D. as chief medical officer.  Full Article

Empery Asset Management reports 9.87 pct passive stake in Vistagen Therapeutics
Friday, 20 May 2016 

Vistagen Therapeutics Inc :Empery Asset Management Lp reports 9.87 pct passive stake in Vistagen Therapeutics Inc, as of May 11, 2016 - SEC filing.  Full Article

BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder

* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER